Three months to go! The 2024 Frost & Sullivan New Investment Conference - Life Sciences New Investment Summit Forum is about to set sail!

The life sciences industry is embracing new opportunities with technological breakthroughs, market growth, and international industrial layout. Against this backdrop, the All-Party Summit of the New Investment Peak Forum in Life Sciences will focus on new heights of industrial development, delving into the latest trends and developments in the global life sciences field. At the conference, Frost & Sullivan will grandly release"Blue Book on the Current Situation and Trends of China's Biopharmaceuticals Going Global in 2024"It provides valuable market insights and strategic guidance for Chinese biopharmaceutical companies in their global layout.

After experiencing continuous changes from darkness to rebirth, the development of China's biopharmaceutical industry faces both challenges and opportunities. Technological innovation continuously writes new chapters in the industry, providing new approaches for treating complex diseases. At the same time, as Chinese biopharmaceutical companies enter an important stage of high-quality development, many enterprises are "setting sail for overseas markets," pushing innovative drugs and medical technologies into international markets in search of broader development space. In the era of incremental growth, the biopharmaceutical industry is driven by innovation, oriented towards clinical value, and taking globalization as an opportunity to advance the industry forward.

Amid the upsurge in developing new quality productivity, the medical device industry is leading industrial innovation with technological innovation into a new era of transformation. With measures to strengthen basic research and cutting-edge technology development, the autonomous supply capacity of underlying technologies and key core technologies has been continuously enhanced, driving the medical device industry towards the mid- to high-end of the global value chain, bringing unprecedented development opportunities to the industry. While Chinese medical device companies are embarking on the journey of 'going global' to seek growth, comprehensive cost reduction and efficiency improvement have also become important ways for the healthcare industry to cope with the unpredictable domestic market. Frost & Sullivan will release this at the conference.Blue Book on the Current Situation and Development Trends of the Medical Supply Chain Fine Management (SPD) IndustryThis blue book will comprehensively sort out the current development status, future trends, and market opportunities of the SPD industry.

The 'Frost & Sullivan' Blue Book on the Current State and Development Trends of the Healthcare Supply Chain (SPD) industry is dedicated to a deep analysis of the core dynamics in China's healthcare supply chain sector. It comprehensively examines the current development status and future direction of the SPD industry. The purpose of this blue book is to provide a comprehensive and in-depth strategic planning for various participants in the industry, including corporate decision-makers, policymakers, and investors. The release of this blue book will enhance market participants' understanding of the SPD industry, including the industry environment, competitive landscape, and emerging market opportunities. It is hoped that through this platform, all parties in the industry can jointly draw a modern development blueprint for China's healthcare supply chain industry and work together to promote the industry towards higher efficiency and intelligence. In addition, the blue book will also provide a stage for participating enterprises to showcase their technical strength, market strategies, and business advantages, promote knowledge sharing and best practice exchanges within the industry, and jointly stimulate the innovative vitality and continuous progress of China's SPD industry.